GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » 3-Year FCF Growth Rate

Nanoform Finland (OSTO:NANOFS) 3-Year FCF Growth Rate : 9.80% (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland 3-Year FCF Growth Rate?

Nanoform Finland's Free Cash Flow per Share for the three months ended in Mar. 2025 was kr-0.59.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 9.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Nanoform Finland was 9.80% per year. The lowest was -154.00% per year. And the median was -28.90% per year.


Competitive Comparison of Nanoform Finland's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Nanoform Finland's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's 3-Year FCF Growth Rate falls into.


;
;

Nanoform Finland 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Nanoform Finland  (OSTO:NANOFS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Nanoform Finland 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.

Nanoform Finland Headlines

No Headlines